Evidence map›Paper›PMID 41550986›Full record

ArticleBladder cancer (Amsterdam, Netherlands)

Metastasis-directed radiotherapy for oligometastatic urothelial carcinoma of the bladder and upper tract.

Patrick Carriere, Omar Alhalabi, Jianjun Gao, Amishi Shah, Sangeeta Goswami, Matthew Campbell, Ruitao Lin, Lauren Mayo, Osama Mohamad, Karen Hoffman and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bladder cancer (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Patrick CarriereDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Omar AlhalabiDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jianjun GaoDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Amishi ShahDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sangeeta GoswamiDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Matthew CampbellDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ruitao LinDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lauren MayoDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Osama MohamadDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Karen HoffmanDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Henry MokDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Charmaigne LozanoDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ashish KamatDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Neema NavaiDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kelly BreeDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Byron LeeDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0002-8755-9688
Charles GuoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael RooneyDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chad TangDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Seungtaek ChoiDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Comron HassanzadehDepartment of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0002-8107-2799

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Metastasis-directed therapy (MDT) for oligometastatic cancer is utilized for genitourinary malignancies including prostate and kidney cancers. Clinical research on MDT for urothelial carcinoma (UC) remains sparse, especially as systemic therapy advances have improved outcomes. Objective: We investigated the role of MDT, specifically radiotherapy, for patients with oligometastatic bladder or upper-tract UC. Methods: Data were collated on patients with metastatic UC with 5 or fewer metastatic sites undergoing MDT with ablative radiotherapy with or without preceding systemic therapy during January 2016 to July 2024. Endpoints were progression-free survival (PFS), and overall survival (OS). Cox proportional hazards analysis was conducted to determine the covariates associated with these endpoints. Results: Fifty-two patients were included. Most were men (67%). Median age was 68 years (interquartile range, 62-78). Most had bladder primary tumors (79%). Patients had a median of 1 metastatic site. Most received ≥2 lines of systemic therapy before MDT (60%), whereas 8% received no systemic therapy before MDT. MDT was delivered to all metastases in 71% of cases, whereas the remaining cases (29%) had MDT delivered to select sites. Median follow-up from the diagnosis of metastasis was 32 months (interquartile range, 23-42). Median PFS and OS were 19 months (95% CI, 15-24) and 42 months (95% CI, 24-60), respectively. Conclusions: MDT may serve as an effective adjunct to systemic therapy to improve outcomes of oligometastatic and oligoprogressive UC.

Indexed as

bladder cancermetastasis directed therapyoligometastaticradiationupper tract urothelial carcinomaurothelial carcinoma

Identifiers

PMID41550986
PMCPMC12804661

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.